drugset
drugset / Trial / NCT04219579

Antithrombin III Concentrate After Liver Transplantation

NCT04219579 ↗

Completed 130 enrolled Seoul National University Hospital
RandomizedParallel-groupTriple-blindPrevention

Summary

This study was designed to demonstrate more effective administration method of AT-III in immediate post-liver transplantation period.

Timeline

Start
2020-01-03
Primary completion
2022-06-28
Completion
2022-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Antithrombin III Protein / enzyme biologic 500 iu —
Subject Antithrombin III Protein / enzyme biologic 3000 iu —

Indications

No indication recorded.